| scholarly article | Q13442814 |
| P50 | author | Katherine R Walter | Q92766143 |
| Christy R Hagan | Q94546337 | ||
| P2093 | author name string | Justin M Balko | |
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| Zika Virus Targets Human STAT2 to Inhibit Type I Interferon Signaling | Q24261402 | ||
| Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
| NS5 of dengue virus mediates STAT2 binding and degradation | Q24644381 | ||
| Regulation of type I interferon responses | Q26853177 | ||
| The STING pathway and the T cell-inflamed tumor microenvironment | Q27008371 | ||
| Type I interferon response and innate immune sensing of cancer | Q27023235 | ||
| Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells | Q28248489 | ||
| Type I interferon is selectively required by dendritic cells for immune rejection of tumors | Q28248500 | ||
| The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data | Q28266682 | ||
| Interferons and their stimulated genes in the tumor microenvironment | Q33988567 | ||
| Immunotherapy of Breast Cancer. | Q50962449 | ||
| STAT2-dependent immune responses ensure host survival despite the presence of a potent viral antagonist. | Q54216757 | ||
| Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer. | Q55310990 | ||
| Managing side effects in adjuvant endocrine therapy for breast cancer | Q57104913 | ||
| Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers | Q57286101 | ||
| Tumor mutational burden is a determinant of immune-mediated survival in breast cancer | Q58567735 | ||
| High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors | Q60931630 | ||
| IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells | Q88645659 | ||
| Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance) | Q91006465 | ||
| A molecular switch from STAT2-IRF9 to ISGF3 underlies interferon-induced gene transcription | Q91564570 | ||
| Progesterone Receptor Attenuates STAT1-Mediated IFN Signaling in Breast Cancer | Q92766147 | ||
| CRISPR/Cas9-based Knockout Strategy Elucidates Components Essential for Type 1 Interferon Signaling in Human HeLa Cells | Q92809603 | ||
| Recent Findings in the Regulation of Programmed Death Ligand 1 Expression | Q93147363 | ||
| Tracking progesterone receptor-mediated actions in breast cancer | Q34388848 | ||
| New Immunotherapy Strategies in Breast Cancer | Q34549227 | ||
| Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort | Q34552706 | ||
| STAT2/IRF9 directs a prolonged ISGF3-like transcriptional response and antiviral activity in the absence of STAT1. | Q35494968 | ||
| STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells | Q36161667 | ||
| Endocrine resistance in breast cancer--An overview and update | Q36386322 | ||
| Hormone replacement therapy and the risk of breast cancer | Q37909897 | ||
| Cancer immunotherapy: accomplishments to date and future promise | Q38151738 | ||
| STAT2 and IRF9: Beyond ISGF3. | Q38185399 | ||
| Mechanisms underlying the inhibition of interferon signaling by viruses | Q38185897 | ||
| Immune evasion in cancer: Mechanistic basis and therapeutic strategies. | Q38394302 | ||
| Interferon-Stimulated Genes Are Transcriptionally Repressed by PR in Breast Cancer | Q38697912 | ||
| The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. | Q38800260 | ||
| Progesterone Receptor Signaling Mechanisms | Q38886936 | ||
| Type I Interferon in Chronic Virus Infection and Cancer. | Q39349338 | ||
| Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3 ligase | Q40179439 | ||
| Different STAT Transcription Complexes Drive Early and Delayed Responses to Type I IFNs | Q41944558 | ||
| Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. | Q46108181 | ||
| Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden | Q47370837 | ||
| Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders. | Q49661424 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 1 | |
| P304 | page(s) | 1758547 | |
| P577 | publication date | 2020-04-30 | |
| P1433 | published in | OncoImmunology | Q18026500 |
| P1476 | title | Progesterone receptor promotes degradation of STAT2 to inhibit the interferon response in breast cancer | |
| P478 | volume | 9 |
Search more.